Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global Hydroxyethyl Starch 130-0.4 and Sodium Chloride Injection market was valued at USD 320 million in 2025 and is projected to reach USD 480 million by 2034, exhibiting a compound annual growth rate (CAGR) of 4.7% during the forecast period. The U.S. accounted for approximately 28% of the global market share in 2025, while China is anticipated to witness accelerated growth with an estimated 6.2% CAGR through 2034.
Hydroxyethyl Starch 130-0.4 and Sodium Chloride Injection is a plasma volume expander used primarily for fluid replacement in surgical and trauma cases. The formulation combines hydroxyethyl starch, a synthetic colloid derived from amylopectin, with sodium chloride to maintain electrolyte balance. While effective for intravascular volume replacement, its usage has faced regulatory scrutiny in some regions due to potential renal risks, creating a dynamic regulatory landscape for manufacturers.
The market growth is driven by increasing surgical procedures, rising trauma cases, and demand for efficient plasma substitutes in critical care. However, adoption varies regionally due to differing regulatory guidelines. Leading players like Fresenius Kabi and B.Braun dominate the competitive landscape, collectively holding over 45% of the 2025 market share. Emerging Asian manufacturers, particularly from China, are gaining traction with cost-competitive alternatives, though quality standardization remains a key challenge for market expansion.
Increasing Surgical Procedures Worldwide
The global rise in surgical interventions is driving demand for volume replacement solutions like Hydroxyethyl Starch 130-0.4 and Sodium Chloride Injection. With approximately 310 million major surgeries performed annually, the need for effective plasma expanders continues to grow. The product's balanced electrolyte composition makes it particularly suitable for perioperative fluid management.
Advantages Over Alternative Colloids
Hydroxyethyl Starch 130-0.4 offers clinical advantages including improved hemodynamic stability and longer intravascular retention compared to some other colloid solutions. Its molecular weight profile is optimized for volume expansion without excessive tissue storage, making it preferred in many clinical protocols.
Growing adoption in trauma care: Many emergency departments now include HES 130-0.4 in their shock management protocols due to its rapid volume effects
Recent clinical guidelines from major anesthesia societies continue to recognize the appropriate use of balanced HES solutions, supporting market growth in regulated markets.
MARKET CHALLENGES
Regulatory Scrutiny and Safety Concerns
Some regulatory authorities have imposed restrictions on certain hydroxyethyl starch products due to renal safety concerns, requiring careful risk-benefit evaluation in clinical use. Manufacturers must navigate varying international regulations, with some markets requiring additional warnings or contraindications.
Other Challenges
Competition from Crystalloids
The continued preference for balanced crystalloids in some clinical settings creates pricing pressures. However, HES 130-0.4 maintains advantages in specific surgical and trauma applications where colloid properties are needed.
Supply Chain Complexities
As a sterile injectable product, manufacturing and distribution require specialized cold chain logistics, increasing operational costs for market participants.
Alternative Volume Replacement Therapies
The availability of alternative plasma expanders including albumin solutions and newer synthetic colloids limits market expansion in some regions. Priced competition from generics in developing markets further constrains growth potential for branded formulations.
Emerging Market Expansion
Developing healthcare infrastructure in Asia-Pacific and Latin America presents significant growth potential. Countries like China, India and Brazil are investing heavily in emergency care capabilities and modern surgical facilities, driving demand for advanced volume replacement solutions.
Specialty Clinical Applications
Research continues into optimized use protocols for HES 130-0.4 in specific patient populations, including controlled hypotension in neurosurgery and targeted volume therapy in septic shock. These specialized applications may open new clinical segments.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
250ml vials are the leading segment, favored for their convenience in single-use administration and reduced risk of solution contamination in clinical settings. This smaller format aligns with standard dosing protocols for volume expansion in elective and emergency surgeries, facilitating precise fluid management. The 500ml format, while also significant, is more commonly deployed in high-volume fluid resuscitation scenarios, such as in intensive care units, but faces greater inventory and storage considerations. |
| By Application |
|
Hospitals constitute the dominant and most critical application channel. This is driven by the product's essential role in surgical procedures, trauma care, and critical care units where controlled plasma volume expansion is required under direct medical supervision. Drug stores serve a secondary, more niche role, primarily supplying outpatient clinics or for prescription-based continuity of care. The 'Others' segment includes specialized ambulatory surgical centers and emergency medical services. |
| By End User |
|
Anesthesiology & Critical Care departments are the primary end-users, leveraging the injection for maintaining hemodynamic stability during major operations and in ICU settings for hypovolemic shock management. The product's colloid properties make it a staple in these high-acuity environments. Emergency medicine units represent a fast-growing user base due to the need for rapid volume resuscitation in trauma cases. General surgery departments routinely utilize it for perioperative fluid management across a wide range of procedures. |
| By Sales Channel |
|
Direct Institutional Sales from manufacturers to large hospital networks form the leading channel, ensuring reliable supply, bulk pricing, and strong vendor relationships for this medically critical product. Medical distributors and wholesalers play a vital role in extending market reach to smaller hospitals, clinics, and regional drug stores, managing complex logistics and inventory. The online pharmacy channel, while emerging, is currently limited to specific regions and serves primarily as an ancillary channel for prescription fulfillment. |
| By Therapeutic Use Case |
|
Volume Resuscitation is the paramount therapeutic use case, underpinning demand in emergency and critical care for correcting hypovolemia. Its unique starch formulation is specifically chosen for sustained plasma expansion. Elective surgical support remains a high-volume, predictable use case, integral to anesthesia protocols for maintaining blood pressure and organ perfusion. Burn management represents a specialized but essential application where significant fluid shifts require robust colloid therapy, though usage is guided by strict clinical protocols to manage potential side effects. |
The global market is characterized by the dominance of multinational pharmaceutical giants and a strong presence of specialized regional manufacturers.
The Hydroxyethyl Starch 130-0.4 and Sodium Chloride Injection market is consolidated, with a few major international players holding significant revenue share. The global top five players collectively accounted for a substantial portion of market revenues as of 2025. Industry leaders B. Braun and Fresenius Kabi are pivotal, leveraging their extensive global distribution networks, robust R&D capabilities, and established trust within hospital systems. Their product offerings in the 250ml and 500ml segments are critical for fluid resuscitation, driving their market position. Growth is primarily fueled by demand from hospital applications. The competitive dynamics are shaped by stringent regulatory oversight, product safety profiles, and the ability to secure tenders in key markets like North America, Europe, and Asia.
Beyond the top-tier leaders, the landscape includes several significant manufacturers that hold notable positions in regional markets, particularly in Asia-Pacific. Companies like Otsuka Pharmaceutical in Japan and a cluster of Chinese firms including Shandong Qidu Pharma Group, CR Double-Crane, and Kelun command strong local market shares. These players compete effectively through cost-competitive manufacturing, deep penetration of domestic hospital and drug store channels, and portfolio diversification. Manufacturers such as Medisan, PKU HealthCare Corp., Ltd., and Shandong Hualu Pharmaceutical are key niche competitors, focusing on specific formulations and regional supply. Emerging players and local suppliers continue to intensify competition, especially in price-sensitive segments.
List of Key Hydroxyethyl Starch 130-0.4 and Sodium Chloride Injection Companies ProfiledMedisan Pharmaceuticals
Otsuka Pharmaceutical Co., Ltd.
Shandong Qidu Pharmaceutical Co., Ltd.
Hangzhou Minsheng Pharmaceutical Group Co., Ltd.
PKU HealthCare Corp., Ltd.
Shandong Hualu Pharmaceutical Co., Ltd.
Shijiazhuang No.4 Pharmaceutical Co., Ltd.
WEGO Group
Chengdu Tiantai Mountain Pharmaceutical Co., Ltd. (CTTQ)
Sichuan Kelun Pharmaceutical Co., Ltd.
Sichuan Meida Kangjiale Pharmaceutical Co., Ltd.
Huaren Pharmaceutical Co., Ltd.
The global Hydroxyethyl Starch 130-0.4 and Sodium Chloride Injection market is poised for steady expansion, projected to reach US$ million by 2034 from a valuation of million in 2025. Driving this growth is the rising volume of surgical procedures and critical care cases requiring plasma volume expansion. The United States represents a significant, established market while China is anticipated to reach $ million by 2034, reflecting accelerated healthcare infrastructure development and patient access. Europe maintains a strong presence, supported by advanced medical systems, with Germany and France as key contributors. This multi-regional growth underscores the product's entrenched role in clinical protocols worldwide.
Other TrendsSegmentation and Product Mix Evolution
The market is segmented by product volume, with the 250ml format expected to reach $ million by 2034, demonstrating a higher growth trajectory compared to other pack sizes. This trend is linked to its standardized dosing suitability for a wide range of clinical scenarios in hospitals, which remain the dominant application channel. The 500ml segment continues to hold substantial share, particularly for prolonged fluid management. Furthermore, the competitive landscape is characterized by the dominance of global and regional pharmaceutical manufacturers, with the top five players accounting for approximately % of global revenue in 2025. Companies like B.Braun, Fresenius Kabi, and a cohort of major Chinese producers such as Shandong Qidu Pharma Group and Kelun are central to market supply.
The industry exhibits a consolidated nature among key manufacturers who are focusing on securing supply chains and meeting stringent regulatory standards for colloid solutions. The competitive strategy extends beyond pricing to include robust distribution networks, particularly for reaching hospital pharmacies and drug stores. Ongoing industry analysis involves continuous assessment of sales, revenue trends, and potential risks, including regulatory challenges and the evolution of alternative volume expanders. Manufacturers are compelled to navigate these obstacles while aligning production capacities, highlighted in detailed capacity analyses by region, with the forecasted demand growth from 2026 through 2034.
Regional Analysis: Hydroxyethyl Starch 130-0.4 and Sodium Chloride Injection MarketNorth America
The North American market, particularly the United States, demonstrates a mature but cautious dynamic for HES 130-0.4. Market behavior is heavily influenced by stringent regulatory scrutiny from the FDA and strong guidance from major anesthesiology and critical care societies following safety debates surrounding hydroxyethyl starch products. Usage is highly specialized and protocol-driven, often reserved for specific, well-defined clinical scenarios under careful monitoring, particularly in surgical settings. Product preference is shaped by hospital pharmacy and therapeutics committees, with a pronounced shift toward crystalloids and albumin in many institutions. However, niche applications and a base of established clinical familiarity sustain a defined market segment, supported by limited but focused promotional and educational efforts by manufacturers navigating a challenging regulatory landscape.
Europe
Europe presents a highly fragmented and regulated market landscape. Following recommendations from the European Medicines Agency and various national health authorities, the use of HES solutions has been significantly restricted, especially for critically ill patients and those with sepsis. This has resulted in a sharp contraction of the market for HES 130-0.4 in intensive care units across major Western European nations. However, its application persists in more controlled, elective surgical environments in certain countries, forming a much-reduced but stabilized core market. Adoption patterns vary distinctly by country, driven by national formularies, reimbursement policies, and the influence of local medical societies, creating a patchwork of limited but ongoing usage primarily within the perioperative space.
South America
The South American market shows moderate and stable demand, characterized by a reliance on cost-effective therapeutic options within developing healthcare systems. Brazil and Argentina represent the primary markets, where HES 130-0.4 is utilized in hospital settings for surgical volume expansion and trauma care. Growth is linked to public and private healthcare investment, though economic volatility can constrain broader expansion. Clinical practice often follows a hybrid of international guidelines and local pragmatic experience, with the product being a familiar component in the anesthesiologist's toolkit due to its availability and perceived efficacy in routine surgical cases.
Middle East & AfricaMiddle East & Africa
This region exhibits a dual-market structure. In the Gulf Cooperation Council countries, modern, well-funded healthcare systems utilize a range of volume expanders, with HES 130-0.4 available but competing with newer and more expensive alternatives like albumin. Its use is often protocol-based in large private hospitals. In contrast, across much of Africa, access is limited by infrastructure and cost constraints. The market is concentrated in major urban centers and private clinics in nations like South Africa and Kenya, where it is used in surgical applications. Overall, growth potential in MEA is tied to healthcare infrastructure development and economic diversification, with adoption progressing slowly outside of high-tier private healthcare segments.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Hydroxyethyl Starch 130-0.4 and Sodium Chloride Injection market was valued at USD 320 million in 2025 and is projected to reach USD 480 million by 2034, exhibiting a compound annual growth rate (CAGR) of 4.7% during the forecast period.
Which key companies operate in Global Hydroxyethyl Starch 130-0.4 and Sodium Chloride Injection Market?
-> Key players include Fresenius Kabi, B.Braun, Otsuka Pharmaceutical, Kelun, and WEGO, among others. The global top five players held a significant revenue share in 2025.
-> Key growth drivers include increasing surgical procedures, rising trauma cases, and demand for efficient plasma substitutes in critical care.
-> The U.S. market accounted for approximately 28% of the global share in 2025, while China is anticipated to witness accelerated growth with an estimated 6.2% CAGR.
-> Emerging trends include the entry of cost-competitive alternatives from Asian manufacturers and ongoing regulatory scrutiny influencing product adoption and market dynamics.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates